ClinicalTrials.gg
CompletedNCT00520676Updated Aug 10, 2011Results posted

Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

A Phase 3 interventional study of pemetrexed and docetaxel in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-10.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
37th of 223
260 · median 64
Started
2007
with 11 others
Phase 3
44 of 227
4 open now
Registered
59th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 37th largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 44 in phase 3, and was the 59th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with locally advanced or (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment
  • Easter Cooperative Oncology Group () performance status 0 to 2
  • Estimated of at least 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Known or suspected
  • Concurrent administration of any other tumor therapy
  • Serious concomitant disorders
  • Pregnancy or breast feeding
  • Inability or unwillingness to take folic acid or vitamin B12 supplementation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    pemetrexed plus carboplatin

    Drug: pemetrexed 500 milligrams per square meter (mg/m\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum Drug: carboplatin Area Under the Curve (AUC) 5 milligram\*minute/milliLiter (mg\*min/mL), IV, q 21 days x 6 cycles maximum

    Drug: pemetrexed · Drug: carboplatin

  • Active comparator
    docetaxel plus carboplatin

    Drug: docetaxel 75 mg/m\^2, IV, q 21 days x 6 cycles maximum Drug: carboplatin AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

    Drug: docetaxel · Drug: carboplatin

Interventions

  • 500 mg/m\^2, IV, q 21 days x 6 cycles maximum

    Also known as: LY231514, Alimta

  • 75 mg/m\^2, IV, q 21 days x 6 cycles maximum

  • AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

06

What researchers measure

Primary outcomes

  1. Survival Without Grade 3 or 4 Toxicity

    Defined as the time from date of randomization to first date of a Grade 3 or 4 treatment-emergent adverse event (TEAE; as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) or death due to any cause. Grade 3 TEAE: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4 TEAE: Life-threatening consequences; urgent intervention indicated. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored at the date of last contact.

    Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).

Secondary outcomes

  1. Overall Survival (OS)

    OS is the duration from enrollment to death. For participants who are alive, OS is censored at the last contact.

    Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).

  2. Progression-free Survival (PFS)

    Defined as the time from date of first dose to the first observation of disease progression (PD), or death due to any cause.

    Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).

  3. Percentage of Participants With Tumor Response (Response Rate)

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes not meeting above criteria. Response rate (%)=Number of participants with CR+PR/Number of participants analyzed \*100. Disease Control rate=Number of participants with SD+PR+CR/Number of participants analyzed \*100.

    Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).

  4. Survival Without Clinically Important Grade 3 or 4 Toxicity

    Survival without Grade 3 or 4 toxicity is the time from date of randomization to the first date of the following clinically important Grade 3 or 4 TEAEs graded by the Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0: neutropenia (lasting \>5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact.

    Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).

  5. Survival Without Grade 4 Toxicity

    Survival without Grade 4 toxicity is the time from the date of randomization to the first date of a Grade 4 TEAE or death due to any cause. Participants who are alive without experiencing Grade 4 toxicity will be censored for this analysis at the date of last contact.

    Time frame: Baseline to until 218 events (defined as death or Grade 4 toxicity) have been observed (up to 33.3 months).

  6. Number of Participants With Adverse Events (AEs)

    Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.

    Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).

Other outcomes

  1. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of longest diameter of target lesions.

    Time frame: Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).

07

Results

Posted Jul 18, 2011

Participant flow

Participant flow — Overall Study
MilestonePemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Started128132
Received at least 1 dose of study drug118127
Qualified intent-to-treat (q-itt)106105
Completed2729
Not completed101103
Withdrew: Death8481
Withdrew: Lost to follow-up610
Withdrew: Physician decision41
Withdrew: Withdrawal by subject711

Outcome measures

PrimarySurvival Without Grade 3 or 4 Toxicity

Defined as the time from date of randomization to first date of a Grade 3 or 4 treatment-emergent adverse event (TEAE; as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0) or death due to any cause. Grade 3 TEAE: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4 TEAE: Life-threatening consequences; urgent intervention indicated. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored at the date of last contact.

Time frame:
Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Median · months
Survival Without Grade 3 or 4 Toxicity
monthsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Survival Without Grade 3 or 4 Toxicity3.2 (2.1 to 3.7)0.7 (0.5 to 1.2)
Statistical analysis
  • Pemetrexed Plus Carboplatin vs Docetaxel Plus Carboplatin · Log Rank · p = <0.001 (The comparison was conducted at a 1-sided significance level of 0.05.) · Hazard ratio (hr): 0.45 · 95% CI 0.34 to 0.60Cox regression model is used for HR estimate.
SecondaryOverall Survival (OS)

OS is the duration from enrollment to death. For participants who are alive, OS is censored at the last contact.

Time frame:
Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Median · months
Overall Survival (OS)
monthsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Overall Survival (OS)14.9 (12.2 to 19.0)14.7 (10.8 to 19.8)
Statistical analysis
  • Pemetrexed Plus Carboplatin vs Docetaxel Plus Carboplatin · Log Rank · p = 0.934 (The comparison was conducted at a 2-sided significance level of 0.05.) · Hazard ratio (hr): 1.01 · 95% CI 0.72 to 1.42Cox regression model is used for hazard ratio (HR) estimate.
SecondaryProgression-free Survival (PFS)

Defined as the time from date of first dose to the first observation of disease progression (PD), or death due to any cause.

Time frame:
Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Progression-free Survival (PFS)5.8 (4.8 to 6.4)6.0 (4.8 to 6.6)
Statistical analysis
  • Pemetrexed Plus Carboplatin vs Docetaxel Plus Carboplatin · Log Rank · p = 0.800 (The comparison was conducted at a 2-sided significance level of 0.05.) · Hazard ratio (hr): 0.96 · 95% CI 0.72 to 1.29Cox regression model is used for hazard ratio (HR) estimate.
SecondaryPercentage of Participants With Tumor Response (Response Rate)

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes not meeting above criteria. Response rate (%)=Number of participants with CR+PR/Number of participants analyzed \*100. Disease Control rate=Number of participants with SD+PR+CR/Number of participants analyzed \*100.

Time frame:
Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Number · percentage of participants
Percentage of Participants With Tumor Response (Response Rate)
percentage of participantsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Tumor Response Rate34.0 (25.0 to 43.8)23.1 (15.4 to 32.4)
Disease Control Rate74.5 (65.1 to 82.5)64.4 (54.4 to 73.6)
Complete Response0.9 (0.0 to 5.1)0 (0 to 3.5)
Partial Response33.0 (24.2 to 42.8)23.1 (15.4 to 32.4)
Stable Disease40.6 (31.1 to 50.5)41.3 (31.8 to 51.4)
Progressive Disease16.0 (9.6 to 24.4)17.3 (10.6 to 26.0)
Unknown9.4 (4.6 to 16.7)18.3 (11.4 to 27.1)
Statistical analysis
  • Pemetrexed Plus Carboplatin vs Docetaxel Plus Carboplatin · Fisher Exact · p = 0.081 (The comparison of tumor response rates was conducted at a 2-sided significance level of 0.05.) · Odds ratio (or): 1.71 · 95% CI 0.93 to 3.15Logistic regression model is used for odds ratio (OR) estimate.
Other pre-specifiedDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of longest diameter of target lesions.

Time frame:
Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Median · months
Duration of Response
monthsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Duration of Response5.5 (4.0 to 8.1)5.4 (4.4 to 6.7)
Statistical analysis
  • Pemetrexed Plus Carboplatin vs Docetaxel Plus Carboplatin · Log Rank · p = 0.641 (The comparison was conducted at a 2-sided significance level of 0.05.) · Hazard ratio (hr): 0.87 · 95% CI 0.49 to 1.55Cox regression model is used for hazard ratio (HR) estimate.
SecondarySurvival Without Clinically Important Grade 3 or 4 Toxicity

Survival without Grade 3 or 4 toxicity is the time from date of randomization to the first date of the following clinically important Grade 3 or 4 TEAEs graded by the Common Terminology Criteria for Adverse Events \[CTCAE\], version 3.0: neutropenia (lasting \>5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact.

Time frame:
Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Median · months
Survival Without Clinically Important Grade 3 or 4 Toxicity
monthsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Survival Without Clinically Important Grade 3 or 4 Toxicity3.6 (3.0 to 8.0)1.3 (1.1 to 1.9)
Statistical analysis
  • Pemetrexed Plus Carboplatin vs Docetaxel Plus Carboplatin · Log Rank · p = <0.001 (The comparison was conducted at a 2-sided significance level of 0.05.) · Hazard ratio (hr): 0.53 · 95% CI 0.40 to 0.71Cox regression model is used for unadjusted hazard ratio (HR) estimate.
SecondarySurvival Without Grade 4 Toxicity

Survival without Grade 4 toxicity is the time from the date of randomization to the first date of a Grade 4 TEAE or death due to any cause. Participants who are alive without experiencing Grade 4 toxicity will be censored for this analysis at the date of last contact.

Time frame:
Baseline to until 218 events (defined as death or Grade 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Median · participants
Survival Without Grade 4 Toxicity
participantsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Survival Without Grade 4 Toxicity12.2 (8.4 to 14.9)2.0 (1.6 to 3.8)
Statistical analysis
  • Pemetrexed Plus Carboplatin vs Docetaxel Plus Carboplatin · Log Rank · p = <0.001 (The comparison was conducted at a 2-sided significance level of 0.05.) · Hazard ratio (hr): 0.49 · 95% CI 0.35 to 0.66Cox regression model is used for unadjusted hazard ratio (HR) estimate.
SecondaryNumber of Participants With Adverse Events (AEs)

Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.

Time frame:
Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Non-Serious Adverse Events (AEs)94100
Serious Adverse Events (SAEs)2835

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed Plus Carboplatin—28/106 (26.4%)94/106 (88.7%)
Docetaxel Plus Carboplatin—35/105 (33.3%)100/105 (95.2%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
Febrile neutropeniaBlood and lymphatic system disorders0/1069/105
NeutropeniaBlood and lymphatic system disorders2/1068/105
PneumoniaInfections and infestations5/1067/105
LeukopeniaBlood and lymphatic system disorders1/1063/105
Atrial fibrillationCardiac disorders0/1063/105
DiarrhoeaGastrointestinal disorders0/1063/105
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1063/105
Respiratory failureRespiratory, thoracic and mediastinal disorders0/1063/105
ThrombocytopeniaBlood and lymphatic system disorders3/1062/105
VomitingGastrointestinal disorders1/1062/105
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPemetrexed Plus CarboplatinDocetaxel Plus Carboplatin
NeutropeniaBlood and lymphatic system disorders40/10674/105
LeukopeniaBlood and lymphatic system disorders33/10656/105
AlopeciaSkin and subcutaneous tissue disorders10/10645/105
NauseaGastrointestinal disorders43/10637/105
AnaemiaBlood and lymphatic system disorders36/10618/105
DiarrhoeaGastrointestinal disorders12/10630/105
Decreased appetiteMetabolism and nutrition disorders27/10630/105
LymphopeniaBlood and lymphatic system disorders14/10625/105
FatigueGeneral disorders13/10621/105
VomitingGastrointestinal disorders18/10619/105

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed Plus CarboplatinDocetaxel Plus CarboplatinTotal
Mean59.6 ± 10.059.2 ± 10.759.4 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed Plus CarboplatinDocetaxel Plus CarboplatinTotal
Female425597
Male6450114
Region of Enrollment
Region of Enrollment(participants)Pemetrexed Plus CarboplatinDocetaxel Plus CarboplatinTotal
Taiwan3912
Mexico172239
Brazil352560
Australia101424
China201737
Korea, Republic of211839
Smoking Status
Smoking Status(participants)Pemetrexed Plus CarboplatinDocetaxel Plus CarboplatinTotal
Never Smoking344175
Ever Smoking but Quit6153114
Currently Smoking111122
Histology
Histology(participants)Pemetrexed Plus CarboplatinDocetaxel Plus CarboplatinTotal
Adenocarcinoma, lung101121
Adenocarcinoma, not otherwise specified8080160
Large cell carcinoma, lung10919
Carcinoma, lung6511
08

Study locations

20 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ballarat, Victoria 3350, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankston, Victoria 3199, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wendouree, Victoria 3355, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bunbury, Western Australia 6230, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barretos, 14784700, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goiania, 74075040, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santo André, 09060-020, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 01224 010, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100036, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210002, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 120-752, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suwon-City, 442-723, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulsan, 682-714, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Obregon, 85100, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durango, 34208, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexicali, 21000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 11640, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 404, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tao-Yuan, 333, Taiwan
09

References and documents

Publications

  • Pereira JR, Cheng R, Orlando M, Kim JH, Barraclough H. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. Drugs R D. 2013 Dec;13(4):289-96. doi: 10.1007/s40268-013-0032-6. PubMed 24277116 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2007
First posted
Aug 24, 2007
Start
Oct 2007
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Jul 18, 2011
Last update
Aug 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00520676
First posted
Aug 24, 2007
Start date
Oct 2007
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Jul 18, 2011
Last update
Aug 10, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion